<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=6946&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="148083" class="table-">
                
                <td>Nov. 11, 2021, 4:30 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            hACE2 receptor binding inhibition assay expressed as GMFR;hACE2 receptor binding inhibition assay expressed as GMFR;hACE2 receptor binding inhibition assay expressed as GMFR;hACE2 receptor binding inhibition assay expressed as GMFR;hACE2 receptor binding inhibition assay expressed as SCR;hACE2 receptor binding inhibition assay expressed as SCR;hACE2 receptor binding inhibition assay expressed as SCR;hACE2 receptor binding inhibition assay expressed as SCR;Human angiotensin-converting enzyme 2 (hACE2) receptor binding inhibition assay expressed as geometric mean titer (GMT);Human angiotensin-converting enzyme 2 (hACE2) receptor binding inhibition assay expressed as geometric mean titer (GMT);Human angiotensin-converting enzyme 2 (hACE2) receptor binding inhibition assay expressed as geometric mean titer (GMT);Human angiotensin-converting enzyme 2 (hACE2) receptor binding inhibition assay expressed as geometric mean titer (GMT);Neutralizing antibody activity expressed as GMFR;Neutralizing antibody activity expressed as GMFR;Neutralizing antibody activity expressed as GMT;Neutralizing antibody activity expressed as GMT;Neutralizing antibody activity expressed as SCR;Neutralizing antibody activity expressed as SCR;Number of HIV-Negative participants with solicited local AEs;Number of HIV-Negative participants with solicited local AEs;Number of HIV-Negative participants with solicited local AEs;Number of HIV-Negative participants with solicited systemic AEs;Number of HIV-Negative participants with solicited systemic AEs;Number of HIV-Negative participants with solicited systemic AEs;Number of HIV-Negative participants with unsolicited AEs;Number of HIV-Negative participants with unsolicited AEs;Number of HIV-Negative participants with unsolicited AEs;Number of PLWH with solicited local AEs;Number of PLWH with solicited local AEs;Number of PLWH with solicited local AEs;Number of PLWH with solicited systemic AEs;Number of PLWH with solicited systemic AEs;Number of PLWH with solicited systemic AEs;Number of PLWH with unsolicited adverse events (AEs);Number of PLWH with unsolicited AEs;Number of PLWH with unsolicited AEs;Serum IgG antibody levels expressed as geometric mean fold rise (GMFR);Serum IgG antibody levels expressed as geometric mean fold rise (GMFR);Serum IgG antibody levels expressed as geometric mean fold rise (GMFR);Serum IgG antibody levels expressed as geometric mean fold rise (GMFR);Serum IgG antibody levels expressed as seroconversion rate (SCR);Serum IgG antibody levels expressed as seroconversion rate (SCR);Serum IgG antibody levels expressed as seroconversion rate (SCR);Serum IgG antibody levels expressed as seroconversion rate (SCR);Serum Immunoglobulin (IgG) antibody levels expressed as geometric mean enzyme-linked immunosorbent assay units (GMEU);Serum Immunoglobulin (IgG) antibody levels expressed as geometric mean enzyme-linked immunosorbent assay units (GMEU);Serum Immunoglobulin (IgG) antibody levels expressed as geometric mean enzyme-linked immunosorbent assay units (GMEU);Serum Immunoglobulin (IgG) antibody levels expressed as geometric mean enzyme-linked immunosorbent assay units (GMEU)
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            hACE2 receptor binding inhibition assay expressed as GMFR;hACE2 receptor binding inhibition assay expressed as GMFR;hACE2 receptor binding inhibition assay expressed as GMFR;hACE2 receptor binding inhibition assay expressed as GMFR;hACE2 receptor binding inhibition assay expressed as SCR;hACE2 receptor binding inhibition assay expressed as SCR;hACE2 receptor binding inhibition assay expressed as SCR;hACE2 receptor binding inhibition assay expressed as SCR;Human angiotensin-converting enzyme 2 (hACE2) receptor binding inhibition assay expressed as geometric mean titer (GMT);Human angiotensin-converting enzyme 2 (hACE2) receptor binding inhibition assay expressed as geometric mean titer (GMT);Human angiotensin-converting enzyme 2 (hACE2) receptor binding inhibition assay expressed as geometric mean titer (GMT);Human angiotensin-converting enzyme 2 (hACE2) receptor binding inhibition assay expressed as geometric mean titer (GMT);Neutralizing antibody activity expressed as GMFR;Neutralizing antibody activity expressed as GMFR;Neutralizing antibody activity expressed as GMT;Neutralizing antibody activity expressed as GMT;Neutralizing antibody activity expressed as SCR;Neutralizing antibody activity expressed as SCR;Number of HIV-Negative participants with solicited local AEs;Number of HIV-Negative participants with solicited local AEs;Number of HIV-Negative participants with solicited local AEs;Number of HIV-Negative participants with solicited systemic AEs;Number of HIV-Negative participants with solicited systemic AEs;Number of HIV-Negative participants with solicited systemic AEs;Number of HIV-Negative participants with unsolicited AEs;Number of HIV-Negative participants with unsolicited AEs;Number of HIV-Negative participants with unsolicited AEs;Number of PLWH with solicited local AEs;Number of PLWH with solicited local AEs;Number of PLWH with solicited local AEs;Number of PLWH with solicited systemic AEs;Number of PLWH with solicited systemic AEs;Number of PLWH with solicited systemic AEs;Number of PLWH with unsolicited adverse events (AEs);Number of PLWH with unsolicited AEs;Number of PLWH with unsolicited AEs;Serum IgG antibody levels expressed as geometric mean fold rise (GMFR);Serum IgG antibody levels expressed as geometric mean fold rise (GMFR);Serum IgG antibody levels expressed as geometric mean fold rise (GMFR);Serum IgG antibody levels expressed as geometric mean fold rise (GMFR);Serum IgG antibody levels expressed as seroconversion rate (SCR);Serum IgG antibody levels expressed as seroconversion rate (SCR);Serum IgG antibody levels expressed as seroconversion rate (SCR);Serum IgG antibody levels expressed as seroconversion rate (SCR);Serum Immunoglobulin (IgG) antibody levels expressed as geometric mean enzyme-linked immunosorbent assay units (GMEU);Serum Immunoglobulin (IgG) antibody levels expressed as geometric mean enzyme-linked immunosorbent assay units (GMEU);Serum Immunoglobulin (IgG) antibody levels expressed as geometric mean enzyme-linked immunosorbent assay units (GMEU);Serum Immunoglobulin (IgG) antibody levels expressed as geometric mean enzyme-linked immunosorbent assay units (GMEU)
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>